US · KRYS
Krystal Biotech, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Pittsburgh, PA 15203
- Website
- krystalbio.com
Price · as of 2025-12-31
$266.04
Market cap 8.06B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $210.83 | -20.75% |
| Intrinsic Value(DCF) | $180.90 | -32% |
| Graham-Dodd Method(GD) | $77.52 | -70.86% |
| Graham Formula(GF) | $287.69 | +8.14% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | $9.69 | ||||
| 2018 | $22.17 | ||||
| 2019 | $53.49 | $51.93 | |||
| 2020 | $82.81 | ||||
| 2021 | $64.83 | ||||
| 2022 | $73.16 | ||||
| 2023 | $171.84 | $17.77 | $30.69 | ||
| 2024 | $179.93 | $260.29 | $21.43 | $48.69 | $1,436.19 |
| 2025 | $258.81 | $210.83 | $195.37 | $77.52 | $287.69 |
AI valuation
Our deep-learning model estimates Krystal Biotech, Inc.'s (KRYS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $210.83
- Current price
- $266.04
- AI upside
- -20.75%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$180.90
-32% upside
Graham-Dodd
$77.52
-70.86% upside
Graham Formula
$287.69
+8.14% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| KRYS | Krystal Biotech, Inc. | $266.04 | 8.06B | -21% | -32% | -71% | +8% | 36.57 | 6.14 | 19.25 | 39.75 | 28.57 | 6.14 | 92.61% | 41.45% | 52.64% | 18.91% | 42.60% | 17.14% | 0.01 | — | 9.95 | 9.28 | -2.90 | 12800.00% | 3394.00% | 5851.00% | 2.52% | 1.95 | 49.90% | 0.00% | 0.00% | 1.99% | 41.37 | 35.32 | 17.15 | 40.89 |
| ACLX | Arcellx, Inc. | $113.79 | 6.58B | -42% | — | — | — | -28.05 | — | — | -31.38 | -27.10 | — | 0.00% | — | — | -100.68% | 644.58% | -39.69% | — | -10.45 | — | — | 0.00 | 10350.00% | -10000.00% | 11938.00% | -3.31% | — | 541.60% | 0.00% | 0.00% | 0.02% | -25.37 | -30.21 | — | — |
| ALKS | Alkermes plc | $30.10 | 4.97B | +85% | -49% | -41% | -85% | 20.62 | 2.74 | 3.38 | 13.49 | — | 2.87 | 86.31% | 17.21% | 16.37% | 14.72% | 20.15% | 10.64% | 0.04 | 20.69 | 2.06 | 1.70 | -1.57 | -3410.00% | -525.00% | -9987.00% | 0.01% | 0.00 | 0.05% | 0.00% | 0.00% | 6.08% | 17.58 | 8571.26 | 3.02 | 5.27 |
| ARWR | Arrowhead Pharmaceuticals… | $63.27 | 8.86B | +5,558% | +96,147% | -95% | — | 272.90 | 17.63 | 9.91 | 46.50 | — | 17.90 | 97.12% | 11.86% | -0.20% | 9.24% | 42.67% | 2.39% | 0.79 | 1.10 | 4.86 | 4.74 | 0.85 | -9976.00% | 2325815.00% | -12596.00% | 1.91% | 0.92 | 116.49% | 0.00% | 0.00% | 7.42% | 77.94 | 48.86 | 9.24 | 5.43 |
| CRSP | CRISPR Therapeutics AG | $60.14 | 5.77B | -40% | -46% | — | +738% | -9.40 | 2.84 | 1556.91 | -7.08 | -19.15 | 2.84 | -6537.01% | -16191.40% | -16569.77% | -30.18% | -191.73% | -25.81% | 0.21 | — | 13.32 | 13.25 | -0.07 | 4908.00% | -8997.00% | 13911.00% | -6.33% | -2.31 | -116.70% | 0.00% | 0.00% | 0.00% | -6.83 | -11.23 | 1106.51 | 8.49 |
| MTSR | Metsera, Inc. | $70.50 | 7.43B | — | — | — | — | — | — | — | — | — | — | 0.00% | — | — | -108.40% | 1345.61% | -67.48% | 0.03 | -1008.22 | 5.34 | 5.24 | 1.57 | 10947.00% | — | 18254.00% | — | -1.49 | 625.73% | — | 0.00% | — | — | — | — | — |
| PCVX | Vaxcyte, Inc. | $61.74 | 8.86B | — | — | — | — | -11.00 | 3.14 | — | -9.58 | -22.85 | 3.14 | 0.00% | — | — | -25.59% | -61.93% | -23.38% | 0.09 | — | 7.91 | 7.81 | -0.07 | 4816.00% | — | 4089.00% | -7.93% | -3.19 | -44.87% | 0.00% | 0.00% | 0.00% | -7.69 | -10.61 | — | 12.61 |
| PTCT | PTC Therapeutics, Inc. | $68.19 | 5.47B | +340% | +35% | -42% | +1,382% | 7.73 | -25.71 | 3.05 | 4.31 | — | -7.80 | 95.85% | 49.49% | 39.44% | -104.75% | -117.79% | 29.58% | -2.40 | 5.63 | 2.35 | 2.20 | -0.55 | -26448.00% | 11451.00% | -48603.00% | 13.31% | 0.73 | -98.57% | 0.00% | 0.00% | 41.37% | 4.47 | 5.45 | 2.21 | 1.69 |
| PTGX | Protagonist Therapeutics,… | $92.08 | 5.76B | -20% | -55% | — | +72% | — | 9.75 | 130.20 | -42.43 | — | 9.75 | 97.34% | -343.63% | -282.83% | 0.00% | -97.33% | 0.00% | 0.02 | — | 12.71 | 12.49 | 0.92 | -14846.00% | -8941.00% | -6932.00% | 0.94% | 1.27 | 34.52% | 0.00% | — | 0.53% | -34.37 | 96.90 | 118.09 | 66.47 |
| TFX | Teleflex Incorporated | $122.06 | 5.39B | -20% | -55% | — | +315% | -6.06 | 1.76 | 2.75 | 17.49 | — | -7.79 | 56.24% | 2.94% | -45.45% | -24.47% | 1.35% | -12.90% | 0.06 | 0.58 | 2.54 | 0.95 | -0.64 | -146824.00% | -3461.00% | -9972.00% | 0.03% | 0.13 | 0.03% | 1.10% | -6.70% | 36.82% | 90.40 | 3659.08 | 2.66 | 2.01 |
| TGTX | TG Therapeutics, Inc. | $30.09 | 4.78B | +200% | +4,085% | -34% | +845% | 9.49 | 6.55 | 6.88 | 33.25 | 0.54 | 6.55 | 83.62% | 20.01% | 72.56% | 102.75% | 36.31% | 54.50% | 0.01 | 4.61 | 4.10 | 2.91 | -0.58 | 174667.00% | 8732.00% | -3840.00% | -0.59% | -0.16 | -7.36% | 0.00% | 0.00% | 5.57% | 33.32 | -164.45 | 6.67 | 6.21 |
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
- CEO
- Krish S. Krishnan
- Employees
- 275
- Beta
- 0.48
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($180.90 ÷ $266.04) − 1 = -32% (DCF, example).